Gavreto (Pralsetinib) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Gavreto is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, rearranged-during-transfection (RET) fusion-positive, non-small cell lung cancer as detected by an FDA-approved test. Gavreto is also known by its drug name, pralsetinib.

Gavreto is a member of a class of drugs called tyrosine kinase inhibitors. Gavreto is believed to work by inhibiting RET, a kinase involved in tumor invasion, migration, and proliferation, thereby slowing the growth and spread of tumors.

How do I take it?
Prescribing information states that Gavreto is taken orally as a capsule once daily on an empty stomach.

Gavreto should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Gavreto lists common side effects including muscle pain, high blood pressure, fatigue, and constipation.

Rare but serious side effects listed for Gavreto include hemorrhage, liver damage, fetal harm, impaired wound healing, and interstitial lung disease (scarring of the lungs).

For more details about this treatment, visit:

Gavreto — Blueprint Medicines

Pralsetinib (Oral Route) — Mayo Clinic

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in